Dual-specifi city phosphatases are targets of the Wnt/β-catenin pathway and candidate mediators of β-catenin/Ras signaling interactions

Biological Chemistry

Volumn 393, Issue 10, 2012, Pages 1183-1191

  Zeller, Eva ^a   Mock, Katharina ^a   Horn, Moritz ^a   Colnot, Sabine ^b   Schwarz, Michael ^a   Braeuning, Albert ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b INSTITUT COCHIN   (France)

Author keywords

Dusp; Egfr; Liver tumor; Mitogen activated protein kinase

Indexed keywords

BETA CATENIN; DUAL SPECIFICITY PHOSPHATASE 14; DUAL SPECIFICITY PHOSPHATASE 6; PHOSPHATASE; RAS PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN; DUAL SPECIFICITY PHOSPHATASE; DUSP14 PROTEIN, MOUSE; DUSP6 PROTEIN, MOUSE; EGFR PROTEIN, MOUSE; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA;

ANIMAL CELL; ARTICLE; BINDING SITE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; FEEDBACK SYSTEM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; DOG; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NUCLEOTIDE SEQUENCE; RAT; TUMOR CELL LINE;

MURINAE;

ANIMALS; BASE SEQUENCE; BETA CATENIN; CELL LINE, TUMOR; DOGS; DUAL SPECIFICITY PHOSPHATASE 6; DUAL-SPECIFICITY PHOSPHATASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; PROTEIN BINDING; RAS PROTEINS; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 84869480383     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2012-0130     Document Type: Article

References (33)

1. Aydinlik, H., Nguyen, T.D., Moennikes, O., Buchmann, A., and Schwarz, M. (2001). Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of β-catenin-mutated mouse liver tumors. Oncogene 20, 7812-7816.
2. Bos, J.L. (1989). Ras oncogenes in human cancer: a review. Cancer Res. 49, 4682-4689.
3. Braeuning, A. (2009). Regulation of cytochrome P450 expression by Ras- and β-catenin-dependent signaling. Curr. Drug Metab. 10, 138-158.
4. Braeuning, A. and Schwarz, M. (2010). Zonation of heme synthesis enzymes in mouse liver and their regulation by β-catenin and Ha-ras. Biol. Chem. 391, 1305-1313.
5. Braeuning, A., Ittrich, C., Kohle, C., Buchmann, A., and Schwarz, M. (2007a). Zonal gene expression in mouse liver resembles expression patterns of Ha-ras and β-catenin mutated hepatomas. Drug Metab. Dispos. 35, 503-507.
6. Braeuning, A., Menzel, M., Kleinschnitz, E.M., Harada, N., Tamai, Y., Kohle, C., Buchmann, A., and Schwarz, M. (2007b). Serum components and activated Ha-ras antagonize expression of perivenous marker genes stimulated by β-catenin signaling in mouse hepatocytes. FEBS J. 274, 4766-4777.
7. Braeuning, A., Sanna, R., Huelsken, J., and Schwarz, M. (2009). Inducibility of drug-metabolizing enzymes by xenobiotics in mice with liver-specifi c knockout of Ctnnb1. Drug Metab. Dispos. 37, 1138-1145.
8. Braeuning, A., Kohle, C., Buchmann, A., and Schwarz, M. (2011). Coordinate regulation of cytochrome P450 1a1 expression in mouse liver by the aryl hydrocarbon receptor and the β-catenin pathway. Toxicol. Sci. 122, 16-25.
9. Cadoret, A., Ovejero, C., Terris, B., Souil, E., Levy, L., Lamers, W.H., Kitajewski, J., Kahn, A., and Perret, C. (2002). New targets of β-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene 21, 8293-8301.
10. de la Coste, A., Romagnolo, B., Billuart, P., Renard, C.A., Buendia, M.A., Soubrane, O., Fabre, M., Chelly, J., Beldjord, C., Kahn, A., et al. (1998). Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl. Acad. Sci. USA 95, 8847-8851.
11. Dhillon, A.S., Hagan, S., Rath, O., and Kolch, W. (2007). MAP kinase signalling pathways in cancer. Oncogene 26, 3279-3290.
12. Hailfi nger, S., Jaworski, M., Braeuning, A., Buchmann, A., and Schwarz, M. (2006). Zonal gene expression in murine liver: lessons from tumors. Hepatology 43, 407-414.
13. Harada, N., Oshima, H., Katoh, M., Tamai, Y., Oshima, M., and Taketo, M.M. (2004). Hepatocarcinogenesis in mice with β-catenin and Ha-ras gene mutations. Cancer Res. 64, 48-54.
14. Hu, T. and Li, C. (2010). Convergence between Wnt- β-catenin and EGFR signaling in cancer. Mol. Cancer 9, 236.
15. Jaworski, M., Buchmann, A., Bauer, P., Riess, O., and Schwarz, M. (2005). B-raf and Ha-ras mutations in chemically induced mouse liver tumors. Oncogene 24, 1290-1295.
16. Kim, D., Rath, O., Kolch, W., and Cho, K.H. (2007). A hidden oncogenic positive feedback loop caused by crosstalk between Wnt and ERK pathways. Oncogene 26, 4571-4579.
17. Klein, P.S. and Melton, D.A. (1996). A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. USA 93, 8455-8459.
18. Kolch, W. (2005). Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat. Rev. Mol. Cell Biol. 6, 827-837.
19. Loeppen, S., Schneider, D., Gaunitz, F., Gebhardt, R., Kurek, R., Buchmann, A., and Schwarz, M. (2002). Overexpression of glutamine synthetase is associated with β-catenin-mutations in mouse liver tumors during promotion of hepatocarcinogenesis by phenobarbital. Cancer Res. 62, 5685-5688.
20. Love, J.J., Li, X., Case, D.A., Giese, K., Grosschedl, R., and Wright, P.E. (1995). Structural basis for DNA bending by the architectural transcription factor LEF-1. Nature 376, 791-795.
21. Marx-Stoelting, P., Mahr, J., Knorpp, T., Schreiber, S., Templin, M.F., Ott, T., Buchmann, A., and Schwarz, M. (2008). Tumor promotion in liver of mice with a conditional Cx26 knockout. Toxicol Sci. 103, 260-267.
22. Miyoshi, Y., Iwao, K., Nagasawa, Y., Aihara, T., Sasaki, Y., Imaoka, S., Murata, M., Shimano, T., and Nakamura, Y. (1998). Activation of the β-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res. 58, 2524-2527.
23. Owens, D.M. and Keyse, S.M. (2007). Differential regulation of MAP kinase signalling by dual-specifi city protein phosphatases. Oncogene 26, 3203-3213.
24. Pearson, G., Robinson, F., Beers Gibson, T., Xu, B.E., Karandikar, M., Berman, K., and Cobb, M.H. (2001). Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 22, 153-183.
25. Pfaffl, M.W. (2001). A new mathematical model for relative quantifi - cation in real-time RT-PCR. Nucleic Acids Res. 29, e45.
26. Reya, T. and Clevers, H. (2005). Wnt signalling in stem cells and cancer. Nature 434, 843-850.
27. Schreiber, S., Rignall, B., Braeuning, A., Marx-Stoelting, P., Ott, T., Buchmann, A., Hammad, S., Hengstler, J.G., Schwarz, M., and Kohle, C. (2011). Phenotype of single hepatocytes expressing an activated version of β-catenin in liver of transgenic mice. J. Mol. Histol. 42, 393-400.
28. Seger, R. and Krebs, E.G. (1995). The MAPK signaling cascade. FASEB J. 9, 726-735.
29. Stahl, S., Ittrich, C., Marx-Stoelting, P., Kohle, C., Altug-Teber, O., Riess, O., Bonin, M., Jobst, J., Kaiser, S., Buchmann, A., et al. (2005). Genotype-phenotype relationships in hepatocellular tumors from mice and man. Hepatology 42, 353-361.
30. Tan, X., Apte, U., Micsenyi, A., Kotsagrelos, E., Luo, J.H., Ranganathan, S., Monga, D.K., Bell, A., Michalopoulos, G.K., and Monga, S.P. (2005). Epidermal growth factor receptor: a novel target of the Wnt/ β-catenin pathway in liver. Gastroenterology 129, 285-302.
31. Torre, C., Benhamouche, S., Mitchell, C., Godard, C., Veber, P., Letourneur, F., Cagnard, N., Jacques, S., Finzi, L., Perret, C., et al. (2011). The transforming growth factor- α and cyclin D1 genes are direct targets of β-catenin signaling in hepatocyte proliferation. J. Hepatol. 55, 86-95.
32. Wong, C.M., Fan, S.T., and Ng, I.O. (2001). B-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic signifi cance. Cancer 92, 136-145.
33. Yan, D., Wiesmann, M., Rohan, M., Chan, V., Jefferson, A.B., Guo, L., Sakamoto, D., Caothien, R.H., Fuller, J.H., Reinhard, C., et al. (2001). Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/ β-catenin signaling is activated in human colon tumors. Proc. Natl. Acad. Sci. USA 98, 14973-14978.